pages:
-
Aging and ARM: Dark Adaptation Impairment
-
Aging and Somatotropic Axis and Abeta Toxicity
-
Aging in Puerto Rico: Longitudinal Follow-Up of the PREHCO Study
-
Aging Well with COPD through Geriatrics-Palliative Care
-
Agonism of DR3 for Enhanced Treg Cell Function in IBD
-
Agreement Between ADPH & Bd of Trustees of the Univ of AL for the Univ of AL "TB Contract"
-
Agreement Between ADPH & Bd of Trustees of the Univ of AL for the Univ of AL "TB Contract"
-
Agreement Between ADPH & The Board of Trustees of the University of AL for the University of Alabama at Birmingham "TB Contract"
-
Agreement Between the ADPH and Board of Trustees of the Univ of AL for the Univ of AL at B'ham "TB Contract"
-
Agreement Between the ADPH and Board of Trustees of the Univ of AL for the Univ of AL at B'ham "TB Contract"
-
Agreement Between The ADPH and The Board of Trustees of the Univ of AL for the Univ of AL at B'ham
-
Agreement for the Collection of Umbilical Cord Blood for the Purpose of Hematopoietic Reconstitution of Unrelated Recipients (Public Use)
-
Agreement ISPM & UAB (2021-2023)
-
Agreement with Alabama Department of Transportation Concerning Historical Worker Accident, Injury, and Illness Data Analysis
-
AHA-Data Grant Fellowship
-
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial)
-
AHEC Point of Service Maint & Enhancement
-
AHEC Point of Service Maint & Enhancement
-
AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
-
AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents
-
AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.
-
AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
-
AHRQ ECHO National Nursing Home COVID-19 Action Network
-
AI4CHRON - An Accessible and Inclusive Artificial Intelligence Assisted Chronic Disease Self-Management Telehealth Platform
-
AIACC Needs Assessment
-
AIDS and Aging Research Platform (AARP)
-
AIDS Clinical Trial Group (ACTG 5324) -- A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV
-
Aids Clinical Trial Group: ACTG
-
AIDS Clinical Trials Group (ACTG)
-
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: PF Chair A5359]
pages:
